leisure time -WSS

leisure time

author：hotspot 2025-09-03 03:46:56 - browse：59849

Scientific watchdogs Sholto David (right) and Elisabeth Bik join STAT's Jonathen Wosen at the STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — According to Elisabeth Bik, a scientific watchdog who has discovered thousands of errors in scientific papers, the problem of fraud, errors, or data mishandling in the scientific literature seems to be getting worse. In the last couple of years, Bik’s been seeing an influx of AI-generated papers in the scientific record that are “nonsensical and clearly low quality.” The possibility that AI-generated, fraudulent data could be making its way into more established journals is a constant fear.

But institutions and academic journals aren’t doing enough about it, she said at the STAT breakthrough summit in San Francisco.

While artificial intelligence can be a powerful research tool when used legitimately, it’s also “absolutely frightening to me what AI can generate,” Bik said. “I’m worried this has already infiltrated scientific literature. It’s hard to tell [AI-generated images] apart from real photos. They look so real. I feel publishers are not putting [in] enough effort to deal with it — how do we find the fake photos?”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Readout Newsletter: Merck, J&J, and long Covid

WSS

Second xenotransplant done with gene

Senate HELP committee spars over health care workforce policies

Parkinson’s finding may lead to tests and, someday, treatments

FDA clears AI tool for detecting skin cancer

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

CDC's new outbreak response network to include Northeastern

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

How to save PrEP access — and even expand it

My yearlong odyssey to get my son’s ADHD medication covered

Apple is now the first public company to be valued at $3 trillion

Francis Collins on trust in science and how Covid communications failed

At least 13 dead in Texas as scorching temps continue

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Peter Hotez and the public health issue of online harassment

Independent physicians launch a new lobbying group

focus

FDA panel to weigh approval of NurOwn, controversial ALS drug

The surgeon had a dilemma only a Nazi medical text could resolve

Biotech lab space demand falls sharply

Why doctors need education on FDA device approval process

Research misconduct: Proposed new rules face resistance

Drug for rare kidney disease narrowly misses mark in clinical trial

hotspot

focus

focus

focus